CD81 marker study in myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a protein called CD81 in blood samples from people with myeloid leukemia. It aims to understand if CD81 levels can help predict how the disease may progress, which could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myeloid leukemia.
- You are newly diagnosed and have not started any treatment yet.
- You are of any age and gender.
- You do not have other blood cancers like ALL, CLL, or plasma cell myeloma.
- You have no other current or past cancers at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study looks at certain proteins on B-cell blood cancer cells to understand them better. It may help doctors learn more about these cancers, but it is not a treatment trial.
This study looks at two markers on blood cells (called CD38 and CD56) in people with chronic myeloid leukemia (CML). It may help doctors understand the disease better.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.